BridgeBio Pharma (BBIO) Capital Expenditures (2018 - 2026)

BridgeBio Pharma has disclosed Capital Expenditures across 9 years of filings, most recently posting $69000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $69000.0, down 79.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $829000.0 (down 30.92% YoY), and the FY2025 annual result was $1.1 million, up 17.58% from the prior year.
• Capital Expenditures came in at $69000.0 for Q1 2026 at BridgeBio Pharma, down from $1.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q4 2025 to a low of -$786000.0 in Q2 2022.
• The 5-year median for Capital Expenditures is $94500.0 (2023), against an average of $215750.0.
• Across the five-year window, Capital Expenditures soared 5792.31% in 2023 and slumped 171.32% in 2025, its largest moves.
• BridgeBio Pharma's Capital Expenditures stood at -$13000.0 in 2022, then soared by 3446.15% to $435000.0 in 2023, then tumbled by 89.2% to $47000.0 in 2024, then soared by 2208.51% to $1.1 million in 2025, then tumbled by 93.64% to $69000.0 in 2026.
• The last three Capital Expenditures figures came in at $69000.0 (Q1 2026), $1.1 million (Q4 2025), and -$582000.0 (Q3 2025), per Business Quant data.